Drug Profile
Research programme: infectious disease vaccines - Zydus Lifesciences
Latest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Bacterial vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diphtheria; Haemophilus infections; Hepatitis A; Hepatitis B; Hepatitis E; Japanese encephalitis; Pertussis; Tetanus; Typhoid
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Diphtheria(Prevention) in India (SC, Injection)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Haemophilus-infections(Prevention) in India (SC, Injection)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Pertussis(Prevention) in India (SC, Injection)